BIO-TECH AIMS TO HEAL
Written on the 17 February 2011
SINCE listing on the ASX in 2004 Tissue Therapies (TIS) has recorded around $14 million in tax losses, but successful clinical trial results have boosted the company’s share price more than three-fold since October. With wound-healing technology that is transforming lives, CEO Steven Mercer tells Brisbane Business News that sales could begin in early-2012.
WHAT started as a unique protein formula developed by Dr Zee Upton at the Queensland University of Technology (QUT) is now on the cusp of tapping into the $7 billion global market for diabetic ulcer treatment.